Every year, 10 million people fall ill with tuberculosis (TB). Despite being preventable and curable, 1.5 million people die from TB yearly – making it the world’s top infectious killer.
Ten million people fall ill with tuberculosis, and often, these symptoms are mild for many months. This leads to delays in seeking care and increases the risk of spreading the infection to others. The WHO recommends rapid molecular diagnostic tests as initial tests for people showing signs and symptoms of tuberculosis (TB).
MycoTact© is in Phase 1 development. This project is designed to show the suitability of the VIPER® platform technology to develop a quick diagnostic test for TB, which will have a significant social impact in Low- and middle-income Countries.